Atrial fibrillation (AF) is the most commonly encountered, sustained cardiac arrhythmia in clinical practice. The risk of developing AF increases with age and tends to be higher in males than in females. The disease presents with a wide spectrum of symptoms and severity and is progressive. Its current global prevalence is around 34 million patients, which is expected to increase as the general population ages. Paroxysmal AF accounts for approximately 39% of all diagnosed prevalent cases of AF.
Paroxysmal supraventricular tachycardia (PSVT) is a common type of abnormal fast heartbeat (tachycardia), estimated to affect 2.25 per 1,000 people or approximately 675,000 people in the US. It is characterized by episodes of faster-than-normal heart rate that can occur at any age and even in people who do not have any other heart disease. Patients with PSVT often have disabling symptoms like palpitations, dizziness and shortness of breath resulting in ER visits, where they are treated with IV drugs. Many patients undergo ablation procedures to prevent recurrences of PSVT. Chronic at-home therapy for prevention of episodes of PSVT employs oral drugs that are suboptimal. InCarda’s lead product InRhythm™ is an inhaled antiarrhythmic therapy that uses an approved drug to be delivered via inhalation and is a potential treatment to rapidly terminate PSVT. InRhythm™ is being developed for treatment of patients with PSVT in an out-of-hospital setting to replace chronic therapy, reduce the need of ER visits, and/or undergo invasive ablation procedures.
InCarda is actively developing therapies for significant unmet needs in cardiovascular medicine and related conditions. Our intellectual property and development expertise are being applied to several additional therapies and diseases with the common goal of reaching clinical development and, ultimately, benefiting patients.